NCT06791291 - Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 25, 2025

Primary Completion Date

March 6, 2028

Study Completion Date

March 6, 2028

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG

Teplizumab

Pharmaceutical form:Solution for injection-Route of administration:Intravenous infusion

Trial Locations (6)

RECRUITING

Investigational Site Number : 3920006, Sapporo

RECRUITING

Investigational Site Number : 3920018, Kobe

RECRUITING

Investigational Site Number : 3920007, Yahaba

RECRUITING

Investigational Site Number : 3920004, Osaka

RECRUITING

Investigational Site Number : 3920001, Iruma

RECRUITING

Investigational Site Number : 3920010, Chuo-chi